BioTuesdays

Category - Markets

Fulcrum Therapeutics
Markets

HCW starts Fulcrum Therapeutics at buy; PT $21

H.C. Wainwright launched coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a “buy” rating and $21 price target. The stock closed at $6.59 on Oct. 2. Fulcrum’s lead program, losmapimod, a p38 alpha/beta MAP kinase...

October 3, 2019
PhaseBio Pharmaceuticals
Markets

HCW starts PhaseBio Pharma at buy; PT $18

H.C. Wainwright initiated coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a “buy” rating and $18 price target. The stock closed at $4.03 on Oct. 2. PhaseBio’s Phase 2 candidate, PB2452, which is licensed from...

October 3, 2019
Fate Therapeutics
Markets

Stifel starts Fate Therapeutics at buy; PT $27

Stifel launched coverage of Fate Therapeutics (NASDAQ:FATE) with a “buy” rating and $27 price target. The stock closed at $15.47 on Sept. 28. Fate is using its induced pluripotent stem cell (iPSC) platform to develop...

September 30, 2019
Daxor
Markets

Roth starts Daxor at neutral; PT $18

Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...

September 30, 2019
Concert Pharma
Markets

Stifel cuts Concert Pharma to hold; PT to $8 from $18

Stifel downgraded Concert Pharmaceuticals (NASDAQ:CNCE) to “hold” from “buy” and lowered its price target to $8 from $18 after the company reported a Phase 3 trial failure with its AVP-786 drug candidate in Alzheimer’s...

September 27, 2019
Hookipa Pharma
Markets

HCW starts Hookipa Pharma at buy; PT $15

H.C. Wainwright launched coverage of HOOKIPA Pharma (NASDAQ:HOOK) with a “buy” rating and $15 price target. The stock closed at $7.76 on Sept. 26. Hookipa is a developing therapies that leverage its proprietary family...

September 27, 2019
Bionomics
Markets

HCW ups Bionomics to buy; PT to 30 cents from 3 cents

H.C. Wainwright upgraded Bionomics (ASX:BNO) to “buy” from “neutral” and raised its price target to 30c (Australian) from three cents after the company announced results of a pharmacokinetics (PK) study of the tablet...

September 26, 2019
NeuBase Therapeutics
Markets

BTIG starts NeuBase Therapeutics at buy; PT $15

BTIG initiated coverage of NeuBase Therapeutics (NASDAQ:NBSE) with a “buy” rating and $15 price target. The stock closed at $6.55 on Sept. 23. NeuBase has developed a modular antisense peptide nucleic acid (PNA)...

September 24, 2019
Alliance Global Partners Logo
Markets

AGP starts coverage of 4 cannabis companies at buy

Alliance Global Partners launched coverage of four cannabis companies – Acreage Holdings (CSE:ACRG; OTCQX:ACRGF), GrowGeneration (OTCQX:GRWG), Village Farms International (TSX:VFF) and Green Thumb Industries...

September 19, 2019